Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in NEC G3/NET G3
NCT02113800Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Aug 2015
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in neuroendocrine carcinoma (NEC) and Neuroendocrine Neoplasm (NEN), sponsored by AIO-Studien. Primary endpoint: Incidence of adverse events. Started Aug 2015; status: completed.
02
Drugs
everolimus
03
Conditions
neuroendocrine carcinoma (NEC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT02113800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113800.